Biotech Values

[Preciouslife1]

http://www.easl.ch/

A Phase 1b Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of MK-7009 in Hepatitis C Infected Patients
Purpose The purpose of this study is to determine whether the study medication will reduce the amount of Hepatitis C virus in the blood of patients who have never been treated for Hepatitis C. Study medication will be taken for 8 days and there is a 36 hour hospital stay and daily visits for blood samples.
Details Study Number
MK-7009 004-02 Accepts Adults? Yes
Accepts Children? No
Fully Enrolled? No

Contacts Principal Investigator
Benedict Maliakkal, M.D. Contact
Cynthia Macdonald, RN, CCRC, [phone]

Maybe you can find something or info in the link above Dew?
Peace...PL1